Back to search results

Dostarlimab and LB-100 for Ovarian Clear Cell Carcinoma

This study is looking at the safety and effectiveness of combining two drugs, dostarlimab and LB-100, for people with ovarian clear cell carcinoma. Researchers want to see if these drugs can help control the cancer. You might be able to join if you are between 18 and 75 years old and have this type of cancer. The main goal is to track any side effects you might experience. They will also look at how well the treatment works to shrink or control the cancer. The study plans to enroll 21 participants.

Study design
This is an interventional study with a planned enrollment of 21 participants. The phase of the study is not specified.
What's involved
You would need to be able to provide signed informed consent and comply with the study protocol, including scheduled visits and examinations, for the duration of the study.
Compensation
Not stated in the trial record.
Follow-up
Adverse events will be measured through study completion, which is an average of 1 year.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06065462

Safety and Efficacy of Targeting PP2A in Ovarian Clear Cell Carcinoma Using Dostarlimab and LB-100

Recruiting
PHASE1Ages 18+InterventionalTreatment
M.D. Anderson Cancer Center
~21 participants
Updated 2026-06-23 on ClinicalTrials.gov
What's tested:DostarlimabLB-100

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0
Measured over through study completion; an average of 1 year

Conditions

Ovarian Clear Cell Carcinoma

Explore related trials

Ovarian Clear Cell Adenocarcinoma

NCT06065462

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • M D Anderson Cancer Center

    Houston, Texasstudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Amir Jazaeri, M D · PRINCIPAL_INVESTIGATOR · M.D. Anderson Cancer Center

Who to contact

Ljiljana Milojevic
[email protected]
(713) 792-8578
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

What this trial measures

  • Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0through study completion; an average of 1 year